Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 122,300 shares, an increase of 35.4% from the December 31st total of 90,300 shares. Based on an average daily volume of 169,400 shares, the short-interest ratio is currently 0.7 days. Approximately 0.3% of the company’s shares are short sold.

Achilles Therapeutics Price Performance

Achilles Therapeutics stock opened at $1.13 on Thursday. The firm’s 50-day moving average is $1.10 and its two-hundred day moving average is $0.96. The stock has a market capitalization of $46.44 million, a P/E ratio of -0.68 and a beta of 1.32. Achilles Therapeutics has a 12-month low of $0.63 and a 12-month high of $1.76.

Institutional Trading of Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd raised its stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 51,660 shares of the company’s stock after purchasing an additional 36,441 shares during the period. XTX Topco Ltd owned 0.13% of Achilles Therapeutics worth $42,000 at the end of the most recent reporting period. 56.38% of the stock is owned by hedge funds and other institutional investors.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.